💥 Welcure Drugs (BSE: 524661) completed 300 cr order ✅ ₹900+ Cr sourcing orders in just 3 weeks ✅ 5% commission = ₹46 Cr revenue potential ✅ Zero debt, asset-light model 💰 Stock price just ₹12 — massively undervalued 📊 Forward P/E under 5 vs industry avg 40+ 🕒 Q1 results due soon — time to act before it flies! 🚀 📌 DYOR but this one screams multibagger potential! ⸻ 🔖 #WelcureDrugs #BSE524661 #MultibaggerStock #PennyStockIndia #UndervaluedGems #SmallCapStock #StockMarketIndia #InvestSmart #ValueInvesting #WealthCreation #StockMarketNews #LongTermStocks #Q1Results #BSEIndia #StockAlert #FinancialIndependenceIndia